Results 221 to 230 of about 25,780 (241)

Randomised Phase II Study Comparing Topotecan/Carboplatin Administration for 5 Versus 3 Days in the Treatment of Extensive-Stage Small-Cell Lung Cancer

Annals of Oncology, 2007
T Fink, C Schade-Brittinger, R Lorenz
exaly  

Topotecan

Der Onkologe, 1998
R. Kath, H. D. Peters, C.-P. Schneider, K. Höffken   +3 more
openaire   +1 more source

Topotecan Plus Carboplatin Versus Standard Therapy With Paclitaxel Plus Carboplatin (PC) or Gemcitabine Plus Carboplatin (GC) or Pegylated Liposomal Doxorubicin Plus Carboplatin (PLDC): A Randomized Phase III Trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG Intergroup Study (HECTOR)

Annals of Oncology, 2016
Antonio González-Martín, Jalid Sehouli, H Woopen   +2 more
exaly  

Topotecan for Relapsed Small Cell Lung Cancer: A Systematic Review and Economic Evaluation

Cancer Treatment Reviews, 2011
Andrew Clegg
exaly  

Topotecan

Inpharma Weekly, 1999
openaire   +1 more source

PK/TD Modeling for Prediction of the Effects of 8C2, an Anti-Topotecan mAb, on Topotecan-Induced Toxicity in Mice

International Journal of Pharmaceutics, 2014
Joseph P Balthasar, Dhaval K Shah
exaly  

Copper–Topotecan Complexation Mediates Drug Accumulation Into Liposomes

Journal of Controlled Release, 2006
Marcel B Bally, Aman Taggar, Euan Ramsay
exaly  

A Comparative Economic Analysis of Pegylated Liposomal Doxorubicin Versus Topotecan in Ovarian Cancer in the USA and the UK

Annals of Oncology, 2002
Michael Drummond, Charles Bennett, S R D Johnston   +2 more
exaly  

Topotecan

Reactions Weekly, 2018
openaire   +1 more source

Development of a Highly Stable and Targetable Nanoliposomal Formulation of Topotecan

Journal of Controlled Release, 2010
Mark E Hayes, Daryl C Drummond, Dmitri B. Kirpotin   +2 more
exaly